Roche breast cancer drug extends overall survival
ZURICH (Reuters) – Swiss pharma group Roche’s drug Perjeta significantly extended the lives of women with an aggressive and incurable form of breast cancer compared to a placebo, according to new data from a late-stage study presented on Saturday. The detailed data presented at the San Antonio Breast Cancer Symposium found that the risk of death was reduced by 34 percent in women treated with a combination treatment of the drugs Perjeta and Herceptin plus chemotherapy compared to women treated with Herceptin, chemotherapy and a placebo, Roche said. . . .
View full post on Health News Headlines – Yahoo! News
Leave a Reply